Investing in blood cancer research: LLS has invested more than $680 million in research, approximately $69 million in fiscal year 2009 alone. Programs like the Specialized Center of Research (SCOR), which brings together teams of scientists from different disciplines and our Translational Research Program, which funds research with a high probability of producing innovative patient treatments in an accelerated time frame, have directly contributed to many breakthrough cancer treatments.
Research funded by LLS has led or contributed to advances such as chemotherapy, bone marrow and stem cell transplantation and new, targeted oral therapies such as Gleevec®.
Providing critical information and support for patients and their families: We made 4.9 million contacts with patients, caregivers and healthcare professionals in fiscal year 2009, through our Information Resource Center (IRC), our award winning Web site and community-based patient service programs. We put people together with experts through Web-casts and teleconferences, and provided professional education through seminars, to extend the latest findings to a broader professional audience.
Advocating for issues impacting blood cancer patients: With more than 20,000 advocacy volunteers throughout the country, our voice is being heard by those responsible for legislation to fund blood cancer research and educational programs.
